Wall Street slips for a third straight day as oil and yields climb

Wall Street indices fell for a third straight day, with the Dow down 0.8%, S&P 500 down 0.5%, and Nasdaq down 0.7%. Oil prices topped $100/barrel, and Treasury yields rose to 4.83%. Investors are concerned about inflation and Fed policy. Apple's event is expected to unveil a foldable iPhone. Several companies reported earnings, with mixed reactions.

Original reporting
Published Sep 9, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wall Street slips for a third straight day as oil and yields climb — source image
Decision brief

The 30-second read

$CASYBearishLow
01

Why it matters

The combination of commodity price spikes and higher borrowing costs creates a risk‑off environment, pressuring equities while rewarding energy and inflation‑hedge assets.

02

Market read

Broad market decline driven by macro factors; individual stock moves reflect earnings surprises and sector sensitivities.

03

What to watch

Mid‑day Treasury buyback announcement could provide temporary support to rates.

Relevance 4/10Novelty 2/10Timing: pre-market today

Background

Wall Street fell for a third day as oil topped $100 and Treasury yields rose to three‑year highs, with mixed corporate earnings.

Company-level read

Ticker impact

$CASYBearishMedium confidence
Context

Casey's General Stores shares fell about 15% after same-store sales missed expectations.

Expected impact

Potential further downside if sales miss persist.

Evidence & confidence

Missed same-store sales is a direct earnings-related catalyst.

$SIGBullishMedium confidence
Context

Signet Jewelers raised its full-year profit forecast after a Q2 earnings beat.

Expected impact

Likely rally on earnings beat and raised guidance.

Evidence & confidence

Guidance lift is a material earnings catalyst.

$CHWYBearishMedium confidence
Context

Chewy's shares fell 8.6% despite earnings beat because free cash flow missed expectations.

Expected impact

Further pressure if cash flow issues continue.

Evidence & confidence

Free cash flow miss is a key financial metric affecting valuation.

$CMPSBullishMedium confidence
Context

Compass Pathways shares rose 4% after Phase III data showed sustained efficacy for its psilocybin treatment.

Expected impact

Potential upside as data supports product pipeline.

Evidence & confidence

Phase III data is a material clinical development event.

Market effects

Higher oil prices and rising yields pressure energy‑heavy and rate‑sensitive sectors.

U.S. equities weakened; global markets likely to follow on commodity and yield moves.

Broad macro backdrop influences risk assets worldwide.

Counterpoint

Despite broad sell‑off, select earnings beatters like Signet may offer upside opportunities.

Key entities

  • Apple

    Hosting a product event; no new financial data disclosed.

  • Treasury Department

    Announced plan to triple upcoming bond buyback size.

Related articles

$CMPSHighAI 9/10

CMPS: Psychedelic therapy for TRD nears FDA approval, promising rapid, durable relief and broad adoption

COMPASS Pathways' psychedelic therapy for treatment-resistant depression is nearing FDA approval, with phase III trials showing rapid and durable efficacy. The company targets a 2027 launch, citing strong payer interest, robust infrastructure, and a large unmet patient need. A PTSD program is also advancing, according to a Morgan Stanley conference transcript.

$CHWYMed

Chewy rises as Goldman Sachs maintains Buy rating on stock

Chewy Inc. shares rose 6.78% to $19.06 after Goldman Sachs maintained a Buy rating but lowered its price target to $34 from $46. The company reported Q1 earnings beat but reduced its fiscal 2026 sales outlook, prompting multiple analysts to cut price targets. Chewy's stock is down 56.34% over the past year and trades near its 52-week low.

$CHWYMedAI 8/10

CHWY Is Still Down 34% This Year: Did CHWY Stock Just Find a Bottom?

Chewy (CHWY) shares rose 6% to $21.75, despite a 34% YTD decline. The company reported 7.3% sales growth, raised full-year revenue guidance, and maintained gross margin at 30.4%. Cash decreased to $611M due to acquisitions and share buybacks. The broader pet-care sector has underperformed, with the PAWZ ETF down 10% YTD. Investors await Q3 2026 results to assess margin expansion and potential bottom.

$CMPSMedAI 9/10

Learn Why The Bull Case For COMPASS Pathways (CMPS) Could Change Following One Year Trial Results

COMPASS Pathways (CMPS) reported 52-week Phase 3 trial data for COMP360 in treatment-resistant depression, showing sustained efficacy and safety. The results suggest long-term symptom relief, impacting future treatment models. Analysts project significant revenue and earnings growth by 2029, with varying upside estimates. The next key catalyst is the Phase 3 COMP006 readout and regulatory progress.